Literature DB >> 11303244

Pregnancy in women with epilepsy : preliminary results of Kerala registry of epilepsy and pregnancy.

S V Thomas1, L Indrani, G C Devi, S Jacob, J Beegum, P P Jacob, K Kesavadas, K Radhakrishnan, P S Sarma.   

Abstract

Eighty-five women with epilepsy were followed up for reproductive functions under the registry of epilepsy and pregnancy. 32 of them had completed the pregnancy. Their mean age was 26 years and mean seizure frequency was 0.7 during current pregnancy. Nineteen of them (59.4%) had generalized epilepsy. Nine of them were not on any anti epileptic drugs (AED), 23 women were on various AEDs, 19 being on monotherapy. Only 40% of the women were taking folic acid during pregnancy. Pregnancy ended as spontaneous abortion in one patient. Nearly one third required cesarean section. Majority (87.5%) had term babies. Three (10.7%) babies had birth asphyxia. Six babies (21.4%) had low birth weight. Congenital malformations were detected in four cases (12.5%). Malformations included neural tube defects, talipes equinovarus and other minor anomalies. These babies were exposed to sodium valproate, carbamazepine or phenobarbitone. The risk of malformation was significantly greater (p<0.05) when the mother had generalized epilepsy. The odds ratio for risk of malformation was much higher with sodium valproate (6) than that with carbamazepine (1.2) or phenobarbitone (0.8). Majority of women with epilepsy had safe pregnancy and childbirth without any aggravation of epilepsy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303244

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  23 in total

1.  Contraception, pregnancy, and peripartum experiences among women with epilepsy in Bhutan.

Authors:  Sheliza Halani; Lhab Tshering; Esther Bui; Sarah J Clark; Sara J Grundy; Tandin Pem; Sonam Lhamo; Ugyen Dema; Damber K Nirola; Chencho Dorji; Farrah J Mateen
Journal:  Epilepsy Res       Date:  2017-10-18       Impact factor: 3.045

Review 2.  Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children.

Authors:  Zixuan Wang; Phoebe W H Ho; Michael T H Choy; Ian C K Wong; Ruth Brauer; Kenneth K C Man
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

Review 3.  Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.

Authors:  Jennifer Weston; Rebecca Bromley; Cerian F Jackson; Naghme Adab; Jill Clayton-Smith; Janette Greenhalgh; Juliet Hounsome; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-11-07

Review 4.  Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management.

Authors:  Timothy E Welty
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 5.  Valproic acid in epilepsy : pregnancy-related issues.

Authors:  Pierre Genton; Franck Semah; Eugen Trinka
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

6.  Pregnancy and epilepsy:update on pregnancy registries.

Authors:  Kaarkuzhali B Krishnamurthy
Journal:  Curr Treat Options Neurol       Date:  2008-07       Impact factor: 3.598

7.  Effect of anti-epileptic drugs in pregnancy and teratogenesis.

Authors:  Sowbhagya Lakshmi; Kulkarni Sunanda
Journal:  Indian J Clin Biochem       Date:  2008-10-01

Review 8.  Headache in pregnancy.

Authors:  Dawn A Marcus
Journal:  Curr Pain Headache Rep       Date:  2003-08

9.  Cardiac malformations are increased in infants of mothers with epilepsy.

Authors:  S V Thomas; B Ajaykumar; K Sindhu; E Francis; N Namboodiri; S Sivasankaran; J A Tharakan; P S Sarma
Journal:  Pediatr Cardiol       Date:  2008-01-08       Impact factor: 1.655

10.  Headache related to pregnancy: management of migraine and migraine headache in pregnancy.

Authors:  Jan Lewis Brandes
Journal:  Curr Treat Options Neurol       Date:  2008-01       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.